Shares of medical supply and logistics company Owens & Minor (NYSE:OMI) jumped 36.9% in the afternoon session after the company reported impressive fourth quarter 2024 results, exceeding analysts' EBITDA and EPS expectations despite delivering in-line revenue. Full-year revenue guidance was also in line, which is comforting. On the other hand, its full-year EPS guidance fell short of Wall Street's estimates. Overall, the quarter was solid, with strong revenue growth, improving margins, and positive guidance.
Is now the time to buy Owens & Minor? Access our full analysis report here, it’s free.
Owens & Minor’s shares are extremely volatile and have had 30 moves greater than 5% over the last year. But moves this big are rare even for Owens & Minor and indicate this news significantly impacted the market’s perception of the business.
Owens & Minor is down 26.5% since the beginning of the year, and at $9.45 per share, it is trading 66.2% below its 52-week high of $27.95 from March 2024. Investors who bought $1,000 worth of Owens & Minor’s shares 5 years ago would now be looking at an investment worth $1,384.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。